IOVANCE BIOTHERAPEUTICS INC (1IOVA.MI) Stock Price & Overview
BIT:1IOVA • US4622601007
Current stock price
The current stock price of 1IOVA.MI is 3.095 EUR. Today 1IOVA.MI is up by 10.14%.
1IOVA.MI Key Statistics
- Market Cap
- 1.275B
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.96
- Dividend Yield
- N/A
1IOVA.MI Stock Performance
1IOVA.MI Stock Chart
1IOVA.MI Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to 1IOVA.MI.
1IOVA.MI Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to 1IOVA.MI. The financial health of 1IOVA.MI is average, but there are quite some concerns on its profitability.
1IOVA.MI Earnings
On February 24, 2026 1IOVA.MI reported an EPS of -0.18 and a revenue of 86.77M. The company missed EPS expectations (-2.78% surprise) and beat revenue expectations (5.4% surprise).
1IOVA.MI Forecast & Estimates
17 analysts have analysed 1IOVA.MI and the average price target is 7.95 EUR. This implies a price increase of 156.75% is expected in the next year compared to the current price of 3.095.
For the next year, analysts expect an EPS growth of 55.58% and a revenue growth 48.26% for 1IOVA.MI
1IOVA.MI Groups
Sector & Classification
1IOVA.MI Financial Highlights
Over the last trailing twelve months 1IOVA.MI reported a non-GAAP Earnings per Share(EPS) of -0.96. The EPS increased by 13.85% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -42.82% | ||
| ROE | -55.97% | ||
| Debt/Equity | 0 |
1IOVA.MI Ownership
1IOVA.MI Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| 1AE | ARGENX SE | 28.81 | 41.518B | ||
| ARGX | ARGENX SE | 29.17 | 41.431B | ||
| 22UA | BIONTECH SE-ADR | N/A | 22.62B | ||
| 2X1 | ABIVAX SA | N/A | 7.62B | ||
| ABVX | ABIVAX SA | N/A | 7.612B | ||
| GXE | GALAPAGOS NV | N/A | 1.607B | ||
| GLPG | GALAPAGOS NV | N/A | 1.605B | ||
| NANO | NANOBIOTIX | N/A | 1.361B | ||
| PHGN | PHARMING GROUP NV | 47.2 | 1.009B | ||
| PHARM | PHARMING GROUP NV | 47.1 | 1.004B | ||
| DBV | DBV TECHNOLOGIES SA | N/A | 946.39M | ||
| DBV | DBV TECHNOLOGIES SA | N/A | 932.473M | ||
| IVA | INVENTIVA SA | N/A | 907.693M |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Euronext Milan Exchange | Find stocks with similar TA and Setup ratings on the European exchanges | Find stocks with similar Fundamental rating on the European exchanges | Find the competitors with the best technical ratings on the European exchanges | Find the competitors with the best fundamentals on the European exchanges | Find the competitors with the best valuation on the European exchanges | Find the competitors with the best dividend on the European exchanges | Find the competitors with the best analyst ratings on the European exchanges
About 1IOVA.MI
Company Profile
Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. The company is headquartered in San Carlos, California and currently employs 975 full-time employees. The company went IPO on 2008-06-20. The company is focused on developing and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer. Its product, Amtagvi, is a tumor-derived autologous T cell immunotherapy indicated for the treatment of adult patients with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600 mutation positive, a BRAF inhibitor with or without a MEK inhibitor. The company is marketing Proleukin (aldesleukin), an interleukin-2 (IL-2) product used in the Amtagvi treatment regimen and in other applications. Amtagvi and Proleukin are part of a treatment regimen that includes lymphodepletion. Its development pipeline includes multicenter trials of TIL cell therapies in additional treatment settings and indications for solid tumor cancers. The company also develops therapies, such as genetically modified TIL cell therapy and cytokines for use in the TIL cell therapy regimen.
Company Info
IPO: 2008-06-20
IOVANCE BIOTHERAPEUTICS INC
825 Industrial Road, 4th Floor
San Carlos CALIFORNIA US
Employees: 975
Phone: 16502607120
IOVANCE BIOTHERAPEUTICS INC / 1IOVA.MI FAQ
Can you describe the business of IOVANCE BIOTHERAPEUTICS INC?
Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. The company is headquartered in San Carlos, California and currently employs 975 full-time employees. The company went IPO on 2008-06-20. The company is focused on developing and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer. Its product, Amtagvi, is a tumor-derived autologous T cell immunotherapy indicated for the treatment of adult patients with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600 mutation positive, a BRAF inhibitor with or without a MEK inhibitor. The company is marketing Proleukin (aldesleukin), an interleukin-2 (IL-2) product used in the Amtagvi treatment regimen and in other applications. Amtagvi and Proleukin are part of a treatment regimen that includes lymphodepletion. Its development pipeline includes multicenter trials of TIL cell therapies in additional treatment settings and indications for solid tumor cancers. The company also develops therapies, such as genetically modified TIL cell therapy and cytokines for use in the TIL cell therapy regimen.
What is the current price of 1IOVA stock?
The current stock price of 1IOVA.MI is 3.095 EUR. The price increased by 10.14% in the last trading session.
Does IOVANCE BIOTHERAPEUTICS INC pay dividends?
1IOVA.MI does not pay a dividend.
How is the ChartMill rating for IOVANCE BIOTHERAPEUTICS INC?
1IOVA.MI has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Is IOVANCE BIOTHERAPEUTICS INC (1IOVA.MI) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on 1IOVA.MI.
What is the next earnings date for 1IOVA stock?
IOVANCE BIOTHERAPEUTICS INC (1IOVA.MI) will report earnings on 2026-05-07.
Can you provide the ownership details for 1IOVA stock?
You can find the ownership structure of IOVANCE BIOTHERAPEUTICS INC (1IOVA.MI) on the Ownership tab.